Company: LNAI
Filing Date: 2025-09-29
Form Type: 10-K
Source: 0001731122-25-001316
Chunk: 39

Company: Lunai Bioworks Inc.
Filing Date: 2025-09-29
Form: 10-K
Item: Item 1A
Chunk 39
---
 as
results of hearings, rulings on motions and other interim proceedings in the litigation. Such announcements could harm our reputation,
the perceived value of our intellectual property or the potential market for our products, which could have a material adverse effect
on our business.

Renovaro
Cube’s and BioSymetrics’ success depends on our ability to develop and commercialize our technology without infringing, misappropriating,
or otherwise violating the intellectual property of third parties. Third parties may initiate legal proceedings alleging that Renovaro
Cube or BioSymetrics is infringing their intellectual property rights, and if they prevail, could block sales of Renovaro Cube’s
or BioSymetrics’ products and force us to make large damages and/or royalty payments, which could have a material adverse effect
on the success of our business.

Renovaro
Cube’s and BioSymetrics’ commercial success in part depends upon our ability, and the ability of our collaborators, to market,
sell and distribute our products and use our proprietary technologies without infringing, misappropriating or otherwise violating the
proprietary rights of third parties. There is considerable intellectual property litigation in the medical technology, biotechnology,
diagnostic and pharmaceutical industries. Renovaro Cube or BioSymetrics may become party to, or threatened with, future adversarial proceedings
or litigation regarding intellectual property rights with respect to its products, including interference proceedings before the United
Kingdom Intellectual Property Office, the European Patent Office, the United States
Patent and Trademark Office and similar bodies in other jurisdictions. Third parties may assert infringement claims against Renovaro Cube
or BioSymetrics based on existing patents or patents that may be issued in the future.

If Renovaro
Cube or BioSymetrics is found to infringe, misappropriate, or otherwise violate a third party’s intellectual property rights, it
could be required to obtain a license from such third party to continue developing, marketing, selling and distributing our products,
or to cease using the infringing technology. However, we may not be able to obtain any required license on commercially reasonable terms
or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the
same technologies licensed to us. In addition, We could be found liable for monetary damages, including treble damages if it is found
to have willfully infringed a patent and attorneys’ fees if the court finds the case to be exceptional. A finding of infringement,
misappropri